FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220982949> ?p ?o ?g. }

• W4220982949 endingPage "100433" @default.
• W4220982949 startingPage "100433" @default.
• W4220982949 abstract "BackgroundScabies is an important predisposing factor of impetigo which can lead to serious bacterial complications. Ivermectin-based mass drug administration can substantially reduce scabies and impetigo prevalence in endemic settings, but the impact on serious bacterial complications is not known.MethodsWe conducted a before-after trial in the Northern Division of Fiji (population: 131,914) of mass drug administration for scabies control. Prospective surveillance was conducted from 2018 to 2020. Mass drug administration took place in 2019, involving two doses of oral ivermectin or topical permethrin, delivered alongside diethylcarbamazine and albendazole for lymphatic filariasis. The primary outcomes were incidence of hospitalisations with skin and soft tissue infections, and childhood invasive infections and post-streptococcal sequelae. Secondary outcomes included presentations to primary healthcare with skin infections and community prevalence of scabies and impetigo.FindingsThe incidence of hospitalisations with skin and soft tissue infections was 17% lower after the intervention compared to baseline (388 vs 467 per 100,000 person-years; incidence rate ratio 0.83, 95% CI, 0.74 to 0.94; P = 0.002). There was no difference in incidence of childhood invasive infections and post-streptococcal sequelae. Incidence of primary healthcare presentations with scabies and skin infections was 21% lower (89.2 vs 108 per 1000 person-years, incidence rate ratio, IRR 0.79, 95% CI, 0.78 to 0.82). Crude community prevalence of scabies declined from 14.2% to 7.7% (cluster-adjusted prevalence 12.5% to 8.9%; prevalence ratio 0.71, 95% CI, 0.28 to 1.17). Cluster-adjusted prevalence of impetigo declined from 15.3% to 6.1% (prevalence ratio 0.4, 95% CI, 0.18 to 0.86).InterpretationMass drug administration for scabies control was associated with a substantial reduction in hospitalisations for skin and soft tissue infections.FundingNational Health and Medical Research Council of Australia and Scobie and Claire Mackinnon Trust." @default.
• W4220982949 created "2022-04-03" @default.
• W4220982949 creator A5003729010 @default.
• W4220982949 creator A5009226230 @default.
• W4220982949 creator A5018260579 @default.
• W4220982949 creator A5021586650 @default.
• W4220982949 creator A5022068438 @default.
• W4220982949 creator A5025372817 @default.
• W4220982949 creator A5035651949 @default.
• W4220982949 creator A5035906789 @default.
• W4220982949 creator A5036929847 @default.
• W4220982949 creator A5045314820 @default.
• W4220982949 creator A5050768046 @default.
• W4220982949 creator A5055059882 @default.
• W4220982949 creator A5065535722 @default.
• W4220982949 creator A5069014035 @default.
• W4220982949 creator A5070811297 @default.
• W4220982949 creator A5072986205 @default.
• W4220982949 creator A5079591035 @default.
• W4220982949 creator A5083477903 @default.
• W4220982949 creator A5083908248 @default.
• W4220982949 creator A5087822392 @default.
• W4220982949 date "2022-05-01" @default.
• W4220982949 modified "2023-10-16" @default.
• W4220982949 title "Prevention of bacterial complications of scabies using mass drug administration: A population-based, before-after trial in Fiji, 2018–2020" @default.
• W4220982949 cites W1787330966 @default.
• W4220982949 cites W1878404532 @default.
• W4220982949 cites W1985493133 @default.
• W4220982949 cites W2011748645 @default.
• W4220982949 cites W2047637153 @default.
• W4220982949 cites W2093274439 @default.
• W4220982949 cites W2098013497 @default.
• W4220982949 cites W2122231026 @default.
• W4220982949 cites W2127585723 @default.
• W4220982949 cites W2133314938 @default.
• W4220982949 cites W2134561148 @default.
• W4220982949 cites W2150173657 @default.
• W4220982949 cites W2160346664 @default.
• W4220982949 cites W2317702186 @default.
• W4220982949 cites W2460458040 @default.
• W4220982949 cites W2759013423 @default.
• W4220982949 cites W2761352074 @default.
• W4220982949 cites W2809778167 @default.
• W4220982949 cites W2870426619 @default.
• W4220982949 cites W2891534801 @default.
• W4220982949 cites W2928276993 @default.
• W4220982949 cites W2944434778 @default.
• W4220982949 cites W2946857541 @default.
• W4220982949 cites W2948825612 @default.
• W4220982949 cites W2957824532 @default.
• W4220982949 cites W3005031357 @default.
• W4220982949 cites W3024453896 @default.
• W4220982949 cites W3108520608 @default.
• W4220982949 cites W3111093735 @default.
• W4220982949 cites W3162276318 @default.
• W4220982949 cites W3165581557 @default.
• W4220982949 cites W4247969168 @default.
• W4220982949 doi "https://doi.org/10.1016/j.lanwpc.2022.100433" @default.
• W4220982949 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35345391" @default.
• W4220982949 hasPublicationYear "2022" @default.
• W4220982949 type Work @default.
• W4220982949 citedByCount "4" @default.
• W4220982949 countsByYear W42209829492022 @default.
• W4220982949 countsByYear W42209829492023 @default.
• W4220982949 crossrefType "journal-article" @default.
• W4220982949 hasAuthorship W4220982949A5003729010 @default.
• W4220982949 hasAuthorship W4220982949A5009226230 @default.
• W4220982949 hasAuthorship W4220982949A5018260579 @default.
• W4220982949 hasAuthorship W4220982949A5021586650 @default.
• W4220982949 hasAuthorship W4220982949A5022068438 @default.
• W4220982949 hasAuthorship W4220982949A5025372817 @default.
• W4220982949 hasAuthorship W4220982949A5035651949 @default.
• W4220982949 hasAuthorship W4220982949A5035906789 @default.
• W4220982949 hasAuthorship W4220982949A5036929847 @default.
• W4220982949 hasAuthorship W4220982949A5045314820 @default.
• W4220982949 hasAuthorship W4220982949A5050768046 @default.
• W4220982949 hasAuthorship W4220982949A5055059882 @default.
• W4220982949 hasAuthorship W4220982949A5065535722 @default.
• W4220982949 hasAuthorship W4220982949A5069014035 @default.
• W4220982949 hasAuthorship W4220982949A5070811297 @default.
• W4220982949 hasAuthorship W4220982949A5072986205 @default.
• W4220982949 hasAuthorship W4220982949A5079591035 @default.
• W4220982949 hasAuthorship W4220982949A5083477903 @default.
• W4220982949 hasAuthorship W4220982949A5083908248 @default.
• W4220982949 hasAuthorship W4220982949A5087822392 @default.
• W4220982949 hasBestOaLocation W42209829491 @default.
• W4220982949 hasConcept C120665830 @default.
• W4220982949 hasConcept C121332964 @default.
• W4220982949 hasConcept C126322002 @default.
• W4220982949 hasConcept C16005928 @default.
• W4220982949 hasConcept C167704817 @default.
• W4220982949 hasConcept C187212893 @default.
• W4220982949 hasConcept C2775983603 @default.
• W4220982949 hasConcept C2777499811 @default.
• W4220982949 hasConcept C2778811088 @default.
• W4220982949 hasConcept C2779489039 @default.
• W4220982949 hasConcept C2781443149 @default.
• W4220982949 hasConcept C2908647359 @default.

• next